What Promet treats: main uses and benefits

Promet (micronized progesterone) is generally used to help manage symptoms related to systemic imbalance and to provide necessary support in specific therapeutic contexts. It is commonly used to help with symptoms related to systemic imbalance in conditions requiring endometrial support and those involving menstrual cycle irregularity.

Endometrial Safety During Hormone Therapy

Promet is commonly used to provide necessary support to the uterine lining, which helps address the structural risk of excessive cell growth (hyperplasia) that may occur when a woman with an intact uterus is exposed to estrogen therapy alone. This use contributes to easing the overall symptom load related to tissue changes and assists with the management of this risk during concurrent hormone treatment. This application may assist with ensuring that hormone therapy is balanced and supports the appropriate response in the uterine tissue.

Managing Symptom Clusters in Secondary Amenorrhea

The medication is used in clinical settings involving conditions where functional stability becomes affected by the absence of expected menstrual bleeding. In these situations, Promet may assist with managing the functional stability of the menstrual cycle, which supports general well-being during symptomatic phases.

---

QuickFact Block

Feature	Detail
Quick Fact: Risk Management	Endometrial protection for postmenopausal women taking estrogen.
Quick Fact: Functional Stability Support	Supports functional stability of the menstrual cycle.

Who can and cannot use Promet?

The eligibility for Promet (micronized progesterone) is strictly defined by regulatory documentation. Use is approved for adult women who require endometrial protection during estrogen therapy or who are being treated for secondary amenorrhea.

Contraindications define absolute non-eligibility. The medicine is contraindicated in patients with known hypersensitivity to the drug or its components (e.g., peanut oil); a history of active thromboembolic disease (including DVT, stroke, or myocardial infarction); known or suspected breast cancer; severe hepatic dysfunction or disease; and undiagnosed abnormal genital bleeding.

Eligibility Restrictions apply to several populations. Safety and effectiveness have not been established in pediatric patients. The medicine is not indicated for use during pregnancy, and caution is advised during lactation. Use requires caution in patients with renal dysfunction and careful monitoring for those with mild to moderate liver dysfunction, as these conditions affect drug elimination.

Eligibility Classifications (High-Level): Official documents classify use as Contraindicated, Established Use, Use with Caution, or Use Not Established (pediatric), based on constraints such as organ function and thrombotic risk.

Interactions with other medicines and products

The official interaction profile for Promet (micronized progesterone) is defined by pharmacokinetic patterns and specific formulation constraints, as documented by regulatory authorities.

---

Pharmacokinetic and Metabolic Interactions

The primary documented interaction is pharmacokinetic, involving the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors, such as Ketoconazole, is documented to significantly increase the plasma concentration and systemic exposure (AUC) of progesterone by inhibiting its metabolism. Conversely, herbal products or supplements known to induce the CYP3A4 enzyme, such as St. John's wort, may potentially decrease progesterone exposure by accelerating its breakdown.

---

Substance, Food, and Condition Restrictions

A formal drug-food interaction is documented, as the ingestion of food increases the bioavailability of the oral capsule formulation compared to administration in a fasting state. In terms of drug-drug effects, the concurrent use of Promet with conjugated estrogens alters estrogen metabolite concentrations, specifically leading to an increase in estrone and equilin. The capsule formulation contains peanut oil, establishing a formal contraindication for individuals with a known peanut allergy. Furthermore, liver dysfunction or disease is a condition-specific restriction noted in the labeling due to the drug’s extensive hepatic metabolism and resulting risk of accumulation.

Histamine and Dopamine Receptor Blockade

Promet's action involves blocking H1 histamine receptors throughout the central nervous system and dopamine D2 receptors in the brain's emetic center. This dual antagonism modulates the signaling for arousal and the emetic reflex, resulting in the physiological effects of CNS depression and inhibition of the emetic reflex.

---

Modulating the Cholinergic and Adrenergic Systems

Promet also functions as an antagonist at muscarinic acetylcholine receptors, inhibiting the transmission of parasympathetic signals both centrally and peripherally. This anticholinergic effect is associated with modulation of vestibular signaling and contributes to the general reduction of exocrine secretions and smooth muscle tone. Additionally, the mechanism involves the blockade of alpha1-adrenergic receptors and a non-competitive interaction with NMDA glutamate receptors, further contributing to the drug’s overall CNS depressant profile by modulating excitatory and sympathetic-driven activity.

Promet (micronized progesterone) is administered orally via soft gelatin capsules, available in 100 mg and 200 mg strengths. The use of the medication is based on specific, fixed, and intermittent dosing regimens.

For the purpose of providing endometrial support in women taking estrogen, the standard regimen is a single daily dose of 200 mg. This dose is taken for 12 consecutive days as part of a recurring 28-day cycle. Conversely, for the management of secondary amenorrhea, the dosing involves taking 400 mg once daily for 10 consecutive days. Both uses emphasize a sequential or cyclical pattern, not continuous daily administration.

Regardless of the dose, the administration protocol specifies that the capsule should be taken at bedtime. It is noted that when the 200 mg dose is taken with food, its absorption is increased. Regarding special population constraints, use of the medication is not indicated in pediatric patients.

If a dose is missed, instructions advise that it should be taken as soon as remembered; however, if it is nearly time for the next scheduled dose, the missed dose should be skipped to prevent taking a double amount. These explicit, time-bound instructions define the standardized use protocol for the oral form of the medicine.

Research evidence / Overview of studies for Promet

The clinical evaluation of Promet (micronized progesterone) has primarily focused on research examining the structural response of the uterine lining in women taking estrogen after menopause, and research exploring short-term changes in menstruation for secondary amenorrhea. This summary outlines the types of studies that have explored outcomes related to these conditions, according to official scientific and governmental sources, and identifies where evidence is limited or certainty remains low.

---

Evidence for use in Preventing Endometrial Hyperplasia in Postmenopausal Women

Research examining this use focuses on outcomes related to the structural response of the uterine lining when women with an intact uterus receive estrogen therapy alone. This research involves long-term Randomized Controlled Trials (RCTs), including pivotal studies lasting up to three years.

These pivotal studies explored their effect on the uterine lining over extended periods. The main measurement was evaluated in the studies using a biopsy of the endometrium (uterine lining). Findings describe patterns observed in the studies related to the histological outcome, specifically by assessing the absence or presence of cell overgrowth, known as hyperplasia. Comparative evidence is lacking from long-term, head-to-head RCTs against every other progestogen option for this specific outcome, and follow-up durations were limited for fully understanding extended tissue health patterns beyond the duration of the core trials.

---

Evidence for use in Treating Secondary Amenorrhea

For the conditions characterized by fluctuating or episodic manifestations involving the menstrual cycle, research explored whether the medication was associated with the intended physiological response. The evidence base consists mainly of short-term Randomized Controlled Trials (RCTs) and controlled clinical studies, where research examined outcomes related to physical discomfort.

These studies were evaluated in premenopausal women experiencing secondary amenorrhea. The primary focus of the research was observed in these trials as the presence of withdrawal bleeding (a menstrual-like bleed) following a brief course of the medication. The research design was primarily focused on measuring the immediate physiological response. Consequently, follow-up durations were limited to the short time frame needed to assess a single withdrawal bleed. The research provides limited insight into long-term outcomes related to the stability of the menstrual cycle, and data are still emerging regarding recurrence rates of amenorrhea following treatment.

Key Studies & References Clinical Study NCT00196391: A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea (Includes oral micronized progesterone comparator arm)

Common questions about Promet (FAQ)

Q: Do I need to take Promet forever or only for a short time?

A: Official documents describe the use of this medicine in intermittent or cyclical treatment plans, depending on the condition being addressed. This means that administration is typically scheduled for a certain number of consecutive days within a recurring cycle, rather than continuous use.

Q: Are there age limits for using Promet?

A: The use of Promet is defined for adult women. Official safety and effectiveness data have not been established for use in pediatric patients, meaning the medicine is not indicated for children or adolescents.

Q: Does Promet interact with herbal supplements?

A: Regulatory documents indicate that herbal products that induce the CYP3A4 enzyme—which is involved in breaking down the medicine—may potentially decrease the body's systemic exposure to the drug. For example, official product information specifically mentions St. John’s wort as an inducer.

Q: What is the official description of how Promet works in the body?

A: Promet contains an active ingredient that is chemically identical to the progesterone hormone naturally produced by the human ovary. According to regulatory descriptions, the medication works by inducing specific changes in the uterine lining.

Q: How quickly does Promet usually start to work?

A: The regulatory documents containing pharmacokinetic information describe how the body handles the medicine. Following administration by mouth, the concentration of the drug in the bloodstream typically reaches its maximum level within three hours.

Q: What happens if I stop taking Promet suddenly?

A: The prescribed use of the medicine is generally cyclical and intermittent, meaning stopping it at the end of a scheduled course is a standard protocol. Regulatory labeling addresses the possible occurrence of withdrawal bleeding (a menstrual-like bleed) following the end of a treatment course, consistent with the expected physiological response.

Q: Can Promet cause long-term side effects?

A: Official regulatory information includes safety warnings concerning potential increased risks of serious events associated with long-term use. When the medicine is used in combination with estrogen, these potential risks include blood clots and certain cancers, as observed in long-term studies.

Q: Can I drink alcohol while taking Promet?

A: Regulatory documents describe that the medicine can cause central nervous system (CNS) effects, such as drowsiness and dizziness. The potential for alcohol use to enhance these central nervous system effects is a general consideration for drugs with this safety profile.

Q: Is Promet safe to use if I am pregnant or breastfeeding?

A: The medication is not indicated for use during pregnancy. Caution is also advised regarding use during lactation, as the amount of the medication transferred into breast milk and its potential effects on the infant are unknown.

Q: Does Promet affect blood pressure?

A: While the regulatory label may not directly list blood pressure changes as a common side effect, it does note the potential for thromboembolic events (blood clots). These conditions are related to the circulatory system.

Q: Does Promet affect birth control pills?

A: Regulatory data primarily focuses on the co-administration of Promet with conjugated estrogens, noting that it alters the concentration of certain estrogen metabolites. The specific effects on the concentration or action of typical oral contraceptive formulations are not directly detailed in the prescribing information.

Q: Can Promet affect my ability to drive or operate machinery?

A: Yes, official labeling notes that adverse reactions such as drowsiness and dizziness are frequently reported. Due to these effects on the central nervous system, the product information includes a warning that they may impair the ability to drive or operate complex machinery.

Q: What kind of monitoring or tests are required while taking Promet?

A: The label advises healthcare providers to undertake appropriate diagnostic measures, such as a biopsy or other endometrial evaluation, to rule out malignancy in cases of unexplained vaginal bleeding.

Q: Do older adults react differently to Promet compared to younger adults?

A: The medication is approved for use in postmenopausal women, and the safety profile is based on data that includes women up to 79 years old. Safety information for this drug class may advise caution regarding age-related risks, including risks related to neurological function, for women 65 years and older, as described in certain studies.

Q: How common are serious side effects with Promet?

A: Official regulatory labels list adverse reactions and major safety concerns, classifying them by their frequency. Serious effects, such as blood clots or certain cancers, are reported with a specific incidence rate (percentage) documented in the pivotal clinical trials.

Q: Can Promet affect my mood or mental health?

A: The official label documents common adverse reactions that involve the Nervous System. These include general effects like headache, fatigue, and drowsiness.

Q: Do studies suggest Promet is helpful for [related minor symptom]?

A: The clinical evidence summarized in official documents is primarily limited to outcomes concerning the uterine lining and the presence of withdrawal bleeding (a menstrual-like bleed). Official documents generally do not summarize evidence for effects on unapproved or minor symptoms.

Q: Are there any specific foods I should avoid while on Promet?

A: A critical safety constraint is that the capsule formulation contains peanut oil as an inactive ingredient. For this reason, the product is contraindicated (must not be used) in individuals with a known peanut allergy.

Q: Why is the core ingredient in Promet called [chemical name]?

A: The core ingredient is officially identified in regulatory documents as Progesterone, USP. This designation means it is the micronized form of the chemical substance progesterone, which meets the purity and quality standards of the U.S. Pharmacopeia (USP).

Q: Can Promet cause problems with sleep?

A: Somnolence (drowsiness) is listed as a common adverse reaction in regulatory documentation. This effect is why the official instructions recommend administering the capsule at bedtime.

Q: How long does Promet stay in your system after stopping it?

A: Regulatory documents describe the half-life of the medicine in the body in the Pharmacokinetics section. The half-life is a scientific measurement that indicates the time it takes for the concentration of the drug in the bloodstream to decrease by half.

Official Storage and Disposal Instructions

The storage of Promet capsules must strictly align with regulatory documentation to maintain product integrity.

Storage Requirement	Specification (from Labeling)
Temperature Range	Store at controlled room temperature (15 C to 30 C or 59 F to 86 F).
Environmental Control	Protect from moisture, excess heat, and freezing. Protect from direct light.
Container & Integrity	Keep in the original container and ensure the container is tightly closed. Do not use after the expiration date or if the packaging is damaged.
Child Safety	Must be stored out of the sight and reach of children.

Disposal instructions require that any unused or expired medication must be managed according to local requirements. Official guidance advises against discarding the product in household trash or flushing it down a toilet, recommending instead that patients consult a pharmacist or utilize authorized take-back programs.